August 8, 2011 – Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, announced that the European Patent Office (EPO) has granted European patent No. EP1212055 entitled “Neurotherapeutic compositions comprising a beta-lactam compound.”
This patent covers compounds including clavulanic acid and moxalactam for the treatment of neurological disorders such as depression, anxiety, dementia, Alzheimer’s disease and Parkinson’s disease, as well as their use and pharmaceutical formulation... Rexahn Pharmaceuticals' Press Release -
